Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2013 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Shapiro on Preventative Drugs in Breast Cancer
Dr. Piccart on a 4-Year Follow-Up of the NeoALTTO Trial
Dr. Neumayer Discusses the POWER PIINC Trial
Oncology Conference Articles
Postneoadjuvant Bisphosphonate Benefits in Breast Cancer Linked to Age, Menopausal Status
Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC
The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.
Ramucirumab Does Not Prolong PFS in HER2-Negative Metastatic Breast Cancer
Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.
CTCs Prognostic But Not Helpful In Switching Therapy in MBC
Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.
Carboplatin Improves pCR More Than Bevacizumab in TNBC
The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.
BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable
The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.
No Survival Benefit Found in LRT for Women Presenting With Metastatic Breast Cancer
In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),
PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer
PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.
Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors
A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.
Anastrozole Cuts Breast Cancer Incidence in Half for Women at High Risk
Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.
NeoALTTO Analysis Finds Significant Link Between pCR and Survival
Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.
No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer
Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.
Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC
Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.
Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery
Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.
Benefits of Screening Mammography Not So Inconsistent, After All
The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.
High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab
New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.
SABCS 2013 Preview: Breast Cancer Diagnosis and Treatment
Presentations at the 36th San Antonio Breast Cancer Symposium (SABCS) will tackle key topics and questions regarding the treatment of breast cancer.
FDA Approvals in Bladder Cancer and NSCLC, and 2019 ELCC Highlights
Top 10 Myths and Facts About the HIPAA Privacy Rule
Dr. Topalian on Evolution of PD-1/PD-L1 Agents in Oncology
Waldenstrom: BTK Resistance and Emerging Therapies
Lack of Durable Responses in Current Treatment of mCRC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.